Drugs / TTRNA-xALT
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06514898 | May 2025 → Sep 2027 expected | medulloblastoma non-WNT/non-SHH group 3, medulloblastoma non-WNT/non-SHH group 4 | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT06254326 | Sep 2024 → Dec 2027 expected | oligodendroglioma | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT03334305 | Aug 2018 → Mar 2025 | high grade astrocytic tumor | University of Florida | Terminated | No outcome recorded |
| Phase 1 | NCT03396575 | Jul 2018 → Mar 2025 | diffuse intrinsic pontine glioma | University of Florida | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01326104 | Sep 2010 → Mar 2020 | medulloblastoma, primitive neuroectodermal tumor | University of Florida | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTRNA-xALT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06514898 ↗ |
| Modality | Cell therapy | “autologous tumor-specific T cell immunotherapy (TTRNA-xALT)” NCT01326104 ↗ |
| Route | Intravenous | “by intravenous injection” NCT01326104 ↗ |